Advanced Viral Research Corp.
- May-10-2004
NEW STORY
- ADVR Receives Second $3 Million Installment of Funding
- Apr-20-2004
- Advanced Viral Research Corp. Announces the Resignation of Its Chief
Financial Officer
- Apr-8-2004
- ADVR Appoints Dr. Carol Epstein as Acting Medical Director
- Mar-19-2004
- ADVR Abstract Selected for Presentation at the American Society of
Clinical Oncology's (ASCO) 40th Annual Meeting
- Feb-25-2004
- ADVR Granted a United States Patent for the Treatment of AIDS
- Feb-20-2004
- ADVR Presented Preclinical Data at the 1st ISC International Conference on
Cancer Therapeutics in Florence
- Feb-12-2004
- ADVR Appoints Biotechnology Veteran Elma S. Hawkins As New Chief Executive
Officer
- Feb-4-2004
- ADVR Secures $12 Million Financing
- Jan-27-2004
- ADVR to present at 1st ISC International Conference on Cancer Therapeutics
- Molecular Targets, Pharmacology and Clinical Applications to be held in
Florence, Italy
- Jan-8-2004
- ADVR Granted U.S. Patent for Treatment of Human Papillomavirus Infections
- Dec-30-2003
- ADVR Names Elma S. Hawkins to Board of Directors
- Dec-30-2003
- AVR118 Suppresses Progression of Disease in Animal Model of Multiple
Sclerosis Developed at The Weizmann Institute of Science
- Dec-3-2003
- ADVR Reports AVR118 Inhibits Inflammatory Arthritis in Animal Model and in
Rheumatoid Arthritis Patients in Human Clinical Trial
- Nov-20-2003
- ADVR's AVR118 Granted a Patent in China for the Treatment of AIDS
- Nov-18-2003
- Advanced Viral Research Corp. Announces Retention of James T. D'Olimpio,
MD As 'Spokesperson at Large'
- Nov-10-2003
- ADVR Reports Positive Preliminary Results of AVR118 Clinical Trial in AIDS
Patients Suffering from Body Wasting (Cachexia)
- Aug-28-2003
- ADVR Announces Search for New CEO and Appointment of Interim CEO
- May-16-2003
- ADVR Completes Private Placement Financing Transactions
- Apr-11-2003
- ADVR CEO Hirschman Comments on SARS on ABC World News Tonight
- Mar-24-2003
- ADVR Granted Therapeutic Composition Patent For Product R; U.S. Patent
Awarded for Chemical Structure of Novel Peptide Nucleic Acid
- Mar-18-2003
- ADVR Begins Planning for Late Stage Phase II AIDS Clinical Trial In Israel
- Feb-25-2003
- ADVR Pursuing Options in NY Litigation; Continues to Press Florida Lawsuit
- Jan-9-2003
- ADVR Completes Private Placement Financing Transaction
- Dec-17-2002
- ADVR Files Stock Manipulation Suit in Florida
- Dec-12-2002
- Potential Use of ADVR's Product R to Treat AIDS Is Focus of A&U
Magazine Article
- Nov-14-2002
- ADVR Begins Product R Israeli Clinical Trials; Quintiles Retained to
Monitor/Audit Trials, Selikoff Center to Conduct Trials
- Nov-8-2002
- ADVR Announces Staff Reduction to Conserve Capital to Focus on Israeli
Clinical Trials; Intent to Sell Bahamas Plant; Board Resignations
- Oct-11-2002
- ADVR's Product R Reverses Cancerous Properties of Human Promyelocytic
Leukemia Cells in Laboratory Cultures
- Sep-25-2002
- Dr. Richard S. Kent Joins ADVR Board of Directors
- Sep-18-2002
- Dr. Sidney Pestka Joins ADVR Scientific Advisory Board
- Sep-10-2002
- ADVR Announces Completion of $3 Million Financing; Funds Enable Israeli
Clinical Trials of Product R to Move Forward
- Aug-20-2002
- ADVR's Product R Subject of Published Study on Clinical Trial For
Treatment of HIV/AIDS
- Aug-13-2002
- Paul R. Bishop Joins ADVR Board of Directors
- Aug-13-2002
- ADVR Announces $1.5 Million Investment By Member of Board and Member of
Business Advisory Board
- Aug-13-2002
- ADVR's Product R Approved in Israel for Phase I Study In Patients with
Solid Tumors
- Aug-13-2002
- ADVR's Product R Approved in Israel for Phase I Study in Leukemia and
Lymphoma Patients
- Aug-13-2002
- Roy S. Walzer Joins Board of Directors of Advanced Viral Research Corp.
- Aug-13-2002
- ADVR's Product R Approved in Israel for Phase I/II Study In Patients
Needing Salvage Therapy For AIDS
- Aug-13-2002
- ADVR Names Mayr Communications to Handle Public/Investor Relations; Firm
Brings Extensive Pharmaceutical Industry Experience
- Aug-13-2002
- ADVR Names Eli Wilner Chairman of the Board
- Aug-13-2002
- ADVR's Dr. Hirschman Describes Large Potential Therapeutic Categories for
Product R
- Aug-13-2002
- ADVR Is Assigned Ownership of Two U.S. Patents in Settlement of Litigation
- Aug-13-2002
- ADVR Begins Phase 2 of IND for Topical Treatment Of Genital Warts With
Product R
- Aug-13-2002
- ADVR's Product R Granted Patent for Topical Use In Treatment of Skin
Diseases, Eye Afflictions
- Aug-13-2002
- Dr. Howard Young - Leading Immunologist - Joins the Scientific Advisory
Board Of Advanced Viral Research Corp.
- Aug-13-2002
- Advanced Viral Research Corp. Forms Scientific Advisory Board with Leaders
in Oncology, Hematology, Women's Health Care
- Aug-13-2002
- Advanced Viral Research Corp. Submits Product R Topical Phase 1 Results to
FDA
More news from PR
Newswire...